| __timestamp | Celldex Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 5758000 |
| Thursday, January 1, 2015 | 4011000 | 8423000 |
| Friday, January 1, 2016 | 102026000 | 11986000 |
| Sunday, January 1, 2017 | 96171000 | 15215000 |
| Monday, January 1, 2018 | 66449000 | 15356000 |
| Tuesday, January 1, 2019 | 42672000 | 16660000 |
| Wednesday, January 1, 2020 | 42534000 | 52459000 |
| Friday, January 1, 2021 | 3068000 | 75061000 |
| Saturday, January 1, 2022 | 1400000 | 87221000 |
| Sunday, January 1, 2023 | 3008000 | 83779000 |
Infusing magic into the data realm
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial. Over the past decade, Supernus Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have shown contrasting trends in their cost of revenue. From 2014 to 2023, Supernus Pharmaceuticals experienced a remarkable increase, with costs rising by over 1,350%, peaking in 2022. This surge reflects their aggressive expansion and scaling efforts. In contrast, Celldex Therapeutics saw a dramatic 97% decrease in costs from 2014 to 2022, indicating strategic shifts or operational efficiencies. Notably, 2020 marked a pivotal year for Supernus, with costs jumping by 215% compared to the previous year, possibly due to increased production or new product launches. These insights highlight the diverse strategies and market responses of these two companies, offering a window into the evolving landscape of the biopharma industry.
AbbVie Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Pfizer Inc. and Supernus Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: MorphoSys AG vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs Dyne Therapeutics, Inc.